Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset - HMS LINCS Database

Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

Filter results: >>>>

Cell	Small Molecule	Small Mol Concentration (uM)	Primary Target	Pathway	Mean Normalized Growth Rate Inhibition Value	Increased Fraction Dead
BT-20	Etoposide	10.0	Topo II	Chemotherapy	-0.3834	0.56500
BT-20	Dasatinib	0.001	BCR/ABL	MAPK/nRTK	0.9136	0.01008
BT-20	Dasatinib	0.0031623	BCR/ABL	MAPK/nRTK	0.9090	0.01661
BT-20	Dasatinib	0.01	BCR/ABL	MAPK/nRTK	0.9134	0.02789
BT-20	Dasatinib	0.031623	BCR/ABL	MAPK/nRTK	0.8598	0.04190
BT-20	Dasatinib	0.1	BCR/ABL	MAPK/nRTK	0.6781	0.07382
BT-20	Dasatinib	0.31623	BCR/ABL	MAPK/nRTK	0.5595	0.11968
BT-20	Dasatinib	1.0	BCR/ABL	MAPK/nRTK	0.4638	0.14107
BT-20	Dasatinib	3.1623	BCR/ABL	MAPK/nRTK	0.3868	0.16072
BT-20	Dasatinib	10.0	BCR/ABL	MAPK/nRTK	0.2835	0.16347
BT-20	Trametinib	0.0001	MEK	MAPK/nRTK	1.0624	0.00127
BT-20	Trametinib	0.00031623	MEK	MAPK/nRTK	1.0401	0.00439
BT-20	Trametinib	0.001	MEK	MAPK/nRTK	0.9545	0.01412
BT-20	Trametinib	0.0031623	MEK	MAPK/nRTK	0.8965	0.02484
BT-20	Trametinib	0.01	MEK	MAPK/nRTK	0.8643	0.03949
BT-20	Trametinib	0.031623	MEK	MAPK/nRTK	0.7406	0.06874
BT-20	Trametinib	0.1	MEK	MAPK/nRTK	0.6938	0.08108
BT-20	Trametinib	0.31623	MEK	MAPK/nRTK	0.6192	0.11389
BT-20	Trametinib	1.0	MEK	MAPK/nRTK	0.5034	0.13365
BT-20	Saracatinib	0.001	SRC	MAPK/nRTK	1.0364	0.01093
BT-20	Saracatinib	0.0031623	SRC	MAPK/nRTK	0.9942	0.00784
BT-20	Saracatinib	0.01	SRC	MAPK/nRTK	0.9466	0.01489
BT-20	Saracatinib	0.031623	SRC	MAPK/nRTK	0.9467	0.02156
BT-20	Saracatinib	0.1	SRC	MAPK/nRTK	0.8930	0.02961
BT-20	Saracatinib	0.31623	SRC	MAPK/nRTK	0.8970	0.03479